Humacyte, Inc. (HUMAW) has a negative trailing P/E of -2.5, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 0.2 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -40.58%, forward earnings yield 526.32%.
Criteria proven by this page:
Overall SharesGrow Score: 40/100 with 2/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2019 | -2.3 | 0.00 | 1.47 | 31.45 | - |
| 2020 | -1.9 | -0.06 | 1.79 | 84.91 | - |
| 2021 | -10.9 | 0.12 | 2.37 | 229.44 | - |
| 2022 | -18.2 | 0.22 | 1.86 | 138.94 | - |
| 2023 | -2.7 | 0.00 | 21.68 | 0.00 | - |
| 2024 | -4.0 | -0.23 | -11.36 | 0.00 | - |
| 2025 | -3.7 | 0.05 | 48.86 | 74.54 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2019 | $-4.25 | $6.19M | $-85.42M | -1380.7% |
| 2020 | $-5.52 | $1.49M | $-68.73M | -4609.4% |
| 2021 | $0.94 | $1.26M | $37.54M | 2972% |
| 2022 | $0.62 | $1.57M | $64.22M | 4103.5% |
| 2023 | $-1.07 | $0.00 | $-110.78M | - |
| 2024 | $-1.26 | $0.00 | $-148.7M | - |
| 2025 | $-0.26 | $2.04M | $-40.83M | -2003.6% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-0.44 | $-1.23 – $-0.13 | $13.62M | $8.53M – $18.43M | 1 |
| 2027 | $-0.20 | $-0.56 – $-0.06 | $70.48M | $30.39M – $178.84M | 1 |
| 2028 | $0.96 | $0.29 – $2.65 | $308.39M | $142.23M – $726.4M | 1 |
| 2029 | $1.85 | $0.55 – $5.10 | $520.23M | $239.94M – $1.23B | 1 |
| 2030 | $3.56 | $1.06 – $9.82 | $935.89M | $431.64M – $2.2B | 1 |
